APA (7th ed.) Citation

Li, C., Li, C., Ding, Y., Cai, S., Liu, B. C., & Wang, X. Post-marketing safety concerns with Tislelizumab: A disproportionality analysis of the FDA adverse event reporting system. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Li, Chen, Chen Li, Yi Ding, Shanshan Cai, Bai Cheng Liu, and Xiufeng Wang. Post-marketing Safety Concerns with Tislelizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Frontiers Media S.A.

MLA (9th ed.) Citation

Li, Chen, et al. Post-marketing Safety Concerns with Tislelizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Frontiers Media S.A.